Monoclonal Antibody Regeneron

Regeneron Gets CHMP Backing of Linvoseltamab

Regeneron's linvoseltamab gets positive EU regulatory opinion

Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended conditional marketing authorization of its drug linvoseltamab for the treatment of adults with relapsed and refractory multiple myeloma.

Business Insider · 2d

Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has

MarketWatch · 2d

Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have shown disease progression on the last therapy.

MarketBeat on MSN3d

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...

13d

Why Regeneron's Price May Soon Break Out

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

Pharmaceutical Technology12d

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

Regeneron and Sanofi have collaborated on Dupixent since ... among other secondary endpoints. Dupixent, a fully human ...

Regeneron Pharmaceuticals Unusual Options Activity For February 25

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results